- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Adjunctive KarXT in Subjects with Inadequately Controlled Symptoms of Schizophrenia
This study is looking into a new medication called KarXT for adults with schizophrenia who aren't getting enough relief from their current treatments. It aims to see if KarXT can help reduce symptoms, compared to a dummy pill, over a 6-week period.
For: SchizophreniaBulgaria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
An Open-label Extension Study to Assess the Long-term Safety and Tolerability of Adjunctive KarXT in Subjects with Inadequately Controlled Symptoms of Schizophrenia
This study is looking at the long-term safety of a new medicine called KarXT for people with schizophrenia. It's a follow-up to earlier studies, helping us understand how safe it is when used for a longer time, and if there are any side effects.
For: SchizophreniaBulgaria - RecruitingPHASE3
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
This study is looking into a new medication called KarXT for people with memory problems like Alzheimer's who also experience psychosis. It compares KarXT to a dummy pill to see if it can prevent these symptoms from returning and if it's safe to use.
For: Psychosis Associated With Alzheimer's DiseaseUnited States · Bulgaria · Croatia - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
This study is looking into a new treatment called KarXT + KarX-EC for people with mild to moderate Alzheimer's disease. Researchers want to see if it can help improve memory and thinking, and if it's safe to use.
For: Alzheimer's DiseaseUnited States · Argentina · Australia - RecruitingPHASE3
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
This study looks at the long-term safety of a new medicine, KarXT, for people with changes in their thoughts and feelings due to Alzheimer's disease. Participants have already taken part in similar studies and will continue to be monitored for about a year.
For: Psychosis Associated With Alzheimer's DiseaseUnited States · Argentina · Belgium - RecruitingPHASE3
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
This study looks at a new medicine for agitation in people with Alzheimer's. It aims to see if an experimental drug, given as capsules, is safe and works well over a long time for those who've been in similar studies before.
For: Alzheimer Disease · AgitationUnited States · Argentina · Brazil - RecruitingPHASE3
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
This study is testing a new medicine, KarXT, for people aged 55-90 who have Alzheimer's disease and also experience psychosis (like seeing or hearing things that aren't there, or having strong untrue beliefs). It aims to see if KarXT can help reduce these symptoms and is safe to use.
For: Psychosis Associated With Alzheimer's DiseaseUnited States · Belgium · Canada - AuthorisedTherapeutic confirmatory (Phase III)
CN012-0025: A Phase 3, Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease (ADAGIO-3)
This study looks at a new drug, KarXT, for people with Alzheimer's disease who experience agitation. It's an extension of previous studies, checking the long-term safety and how well people tolerate the medication. Researchers want to see if it causes any unwanted side effects over time.
For: Agitation Associated with Alzheimer’s DiseaseCroatia · Romania · France - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (13 to 17 years of age)
This study is looking into a new medicine called KarXT for teenagers (aged 13-17) who have schizophrenia. Researchers want to see if KarXT can help improve symptoms and if it is safe to use. Some teens will get KarXT, and others will get a dummy medicine.
For: SchizophreniaRomania - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3 Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of KarXT in Adolescents (13 to 17 years of age) with Schizophrenia and KarXT+KarX-EC in Children and Adolescents (5 to 17 years of age) with Irritability Associated with Autism Spectrum Disorder
This study looks at new medicines (KarXT and KarX-EC) for young people aged 5-17. It checks how safe they are and if they cause any side effects for teenagers with schizophrenia or children/teenagers with autism who have a lot of irritability.
For: Schizophrenia and Autism Spectrum Disorder (ASD)Romania - RecruitingPHASE3
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
This study is looking at a new treatment called KarXT + KarX-EC for psychosis, which can affect people with Alzheimer's disease. Researchers want to see if this treatment is safe and helps reduce psychotic symptoms like hallucinations or delusions in individuals aged 55 to 90.
For: Alzheimer Disease · PsychosisUnited States · Australia · Canada